PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 19, 2026Cancer Research0 citations

Abstract LB027: AI guided engineering of pH responsive antibodies enables tumor selective targeting and improves the therapeutic index

View Full Paper
QYQilin YuPingliang People's HospitalMCMingchen ChenPingliang People's HospitalYLYun LuSichuan University

Key Points

  • The study aims to create antibodies that selectively bind to tumors in acidic environments using AI techniques.
  • Developed a deep learning model to predict antibody mutations and their binding changes based on pH.
  • Redesigned a B7-H3-targeting antibody to enhance binding in acidic conditions.
  • Tested the binding affinity of modified antibodies at different pH levels, specifically pH 6.0 and 7.4.
  • Formulated pH-responsive antibodies as antibody-drug conjugates to evaluate therapeutic performance.
  • Achieved over 100-fold higher affinity ratios at pH 6.0 compared to pH 7.4.
  • Demonstrated strong pH-dependent binding, with high affinity retained in acidic conditions.
  • Showed improved selectivity in ADCs with a threefold expansion of the drug administration window compared to the parent antibody.

Abstract

Abstract Tumor tissues exhibit a mildly acidic extracellular microenvironment (pH 6. 0-6. 8), in contrast to normal tissues at physiological pH (∼7. 4), and exploiting this difference could enable tumor-selective antibody targeting and reduce systemic toxicity; however, rationally engineering pH-dependent binding into antibodies remains challenging. We developed an deep learning model that predicts how mutations in antibody complementarity-determining regions (CDRs) modulate antigen binding as a function of pH and applied it to redesign a B7-H3-targeting antibody to preferentially bind under acidic conditions. The resulting antibodies showed strong pH-dependent binding, achieving affinity ratios (pH 6. 0 / pH 7. 4) exceeding 100-fold, with high affinity maintained in acidic conditions representative of the tumor microenvironment and markedly reduced binding at physiological pH. When reformatted as antibody-drug conjugates (ADCs), these pH-responsive antibodies exhibited improved selectivity and a threefold expansion of the drug administration window compared with the parent antibody. These results demonstrate that AI-driven CDR engineering enables systematic design of microenvironment-responsive antibodies and offers a generalizable strategy to enhance the therapeutic index of antibody-based cancer therapeutics. Citation Format: Qilin Yu, Mingchen Chen, Ying Lu, Yuxi Wang. AI guided engineering of pH responsive antibodies enables tumor selective targeting and improves the therapeutic index abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts) ; 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86 (8Suppl): Abstract nr LB027.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Yu et al. (2026) studied this question.

synapsesocial.com/papers/69e47250010ef96374d8e6f5https://doi.org/10.1158/1538-7445.am2026-lb027
Ask AI
Helpful
Bookmark
Share
View Full Paper